Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sunshine Biopharma ( (SBFM) ) has issued an announcement.
On December 11, 2025, Sunshine Biopharma Inc. held its annual meeting of stockholders where key decisions were made. The company elected five directors, ratified the appointment of M&K CPAS, PLLC as its independent registered public accounting firm for 2025, and approved an amendment to increase the number of shares in its 2023 Equity Incentive Plan to 683,000. These actions are likely to impact the company’s governance and financial strategies moving forward.
The most recent analyst rating on (SBFM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Sunshine Biopharma stock, see the SBFM Stock Forecast page.
Spark’s Take on SBFM Stock
According to Spark, TipRanks’ AI Analyst, SBFM is a Neutral.
Sunshine Biopharma’s overall stock score is primarily impacted by its financial performance and technical analysis. The company shows strong revenue growth but struggles with profitability and cash flow management, leading to a low financial performance score. Technical indicators suggest bearish momentum, further weighing down the score. The negative P/E ratio and lack of dividend yield reflect valuation challenges. Without earnings call insights or notable corporate events, these factors dominate the overall assessment.
To see Spark’s full report on SBFM stock, click here.
More about Sunshine Biopharma
Average Trading Volume: 753,637
Technical Sentiment Signal: Sell
Current Market Cap: $7.16M
For detailed information about SBFM stock, go to TipRanks’ Stock Analysis page.